New Takeda President Has Hands Full In Solving Slew Of Problems
This article was originally published in PharmAsia News
Takeda Pharmaceutical's new president said the company needs to focus its efforts on developing just a few drugs and its researchers focusing on quality rather than quantity.
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.